A review of clinical trial designs used to detect a disease-modifying effect of drug therapy in Alzheimer’s disease and Parkinson’s disease
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2377
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
A review of clinical trial designs used to detect a disease-modifying effect of drug therapy in Alzheimer’s disease and Parkinson’s disease ; volume:16 ; number:1 ; day:16 ; month:6 ; year:2016 ; pages:1-13 ; date:12.2016
BMC neurology ; 16, Heft 1 (16.6.2016), 1-13, 12.2016
- Urheber
-
McGhee, David J. M.
- Beteiligte Personen und Organisationen
-
Ritchie, Craig W.
Zajicek, John P.
Counsell, Carl E.
SpringerLink (Online service)
- DOI
-
10.1186/s12883-016-0606-3
- URN
-
urn:nbn:de:1111-2016061722677
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 14.08.2025, 10:50 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- McGhee, David J. M.
- Ritchie, Craig W.
- Zajicek, John P.
- Counsell, Carl E.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Disease-modifying treatments in Alzheimer’s disease
Disease-Modifying Therapies for Alzheimer’s Disease: More Questions than Answers
Parkinson’s disease and Alzheimer’s disease: a Mendelian randomization study
Regulatory and Health Technology Assessment Considerations for Disease-Modifying Drugs in Alzheimer’s Disease
The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease
Alzheimer’s disease tau is a prominent pathology in LRRK2 Parkinson’s disease
Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease
Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease
Measuring compounds in exhaled air to detect Alzheimer´s disease and Parkinson´s disease
Biomarker candidates of neurodegeneration in Parkinson's disease for the evaluation of disease-modifying therapeutics
Correction to: The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease
SNAP25 is a potential target for early stage Alzheimer’s disease and Parkinson’s disease
Disease-modifying treatments in Alzheimer’s disease
Disease-Modifying Therapies for Alzheimer’s Disease: More Questions than Answers
Parkinson’s disease and Alzheimer’s disease: a Mendelian randomization study
Regulatory and Health Technology Assessment Considerations for Disease-Modifying Drugs in Alzheimer’s Disease
The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease
Alzheimer’s disease tau is a prominent pathology in LRRK2 Parkinson’s disease
Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease
Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease
Measuring compounds in exhaled air to detect Alzheimer´s disease and Parkinson´s disease
Biomarker candidates of neurodegeneration in Parkinson's disease for the evaluation of disease-modifying therapeutics
Correction to: The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease
SNAP25 is a potential target for early stage Alzheimer’s disease and Parkinson’s disease
Disease-modifying treatments in Alzheimer’s disease
Disease-Modifying Therapies for Alzheimer’s Disease: More Questions than Answers
Parkinson’s disease and Alzheimer’s disease: a Mendelian randomization study
Regulatory and Health Technology Assessment Considerations for Disease-Modifying Drugs in Alzheimer’s Disease
The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease
Alzheimer’s disease tau is a prominent pathology in LRRK2 Parkinson’s disease
Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease
Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease
Measuring compounds in exhaled air to detect Alzheimer´s disease and Parkinson´s disease
Biomarker candidates of neurodegeneration in Parkinson's disease for the evaluation of disease-modifying therapeutics
Correction to: The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease